Pipeline
Analysis of Hospital Acquired Pneumonia Drugs Market (Tedizolid
Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin
Inhale, Plazomicin, and Synflorix) - Global Industry Analysis, Size,
Share, Growth, Trends and Forecast, 2014 - 2020" six phase III
drugs would generate total revenue of USD 3.8 billion by 2020.
Browse
the full Pipeline Analysis of Hospital Acquired Pneumonia Drugs
Market Report at
http://www.transparencymarketresearch.com/hospital-acquired-pneumonia-drugs.html
Hospital
acquired infections also called as healthcare associated infections
or nosocomial infections have raised serious concerns due to
multidrug resistance shown by microorganisms. Multidrug resistant
organisms are immune to the conventional antibiotics, hence very
difficult to treat. Pneumonia accounts for over 22% of all the
hospital acquired infections. Since hospital acquired pneumonia is
mainly caused as a result of prolonged exposure to ventilator, it is
also called as ventilator associated pneumonia. The infection is
common in immunocompromised patients, post surgical infections,
enteral feeding, and in elderly and infant patients. Various gram
positive as well as gram negative bacteria are known to cause
hospital acquired pneumonia. Major causative agents include
methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P.
aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus
(RSV) is found to be a major causative agent of nosocomial pneumonia
in new borne.
Currently
there are five investigational drugs and one vaccine in stage III
clinical trials, while ten other candidates in early stage. Phase III
candidates include Tedizolid phosphate and Ceftolozane/tazobactam by
Cubist Pharmaceuticals, Ceftazidime/avibactam by AstraZeneca PLC,
Amikacin inhale by Bayer Healthcare, Plazomicin by Achaogen, Inc. and
Synflorix by GlaxoSmithKline.
Request
for customization of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1881
Majority
of these drugs are expected to be launched by 2017. Analysis reveals
that majority of the candidates in late stage are biological drugs.
This indicates a paradigm shift from traditional antibiotic therapy
to more sophisticated biological drug therapy. Aridis Pharmaceuticals
hold a strong monoclonal antibody pipeline with four candidates for
treatment of hospital acquired pneumonia which was acquired from
Kenta Biotech in 2013.
Growing
drug resistance has been a major concern in hospitals globally.
According to a report published by Centers for Disease Control and
Prevention (CDC) in 2013 which considers the U.S. population for
study, 63% of Acinetobacter is considered multi drug resistant.
Methicillin resistant Staphylococcus aureus (MRSA) is one of the most
hazardous organisms causing ventilator-associated pneumonia. CDC
estimates that over 80,400 MRSA infections occurred in 2011, of which
more than 11,000 patients died. Furthermore, World Health
Organization (WHO) suggests that prevalence of nosocomial infections
is higher in low and middle income countries. This suggests that the
conditions are more alarming in these regions. In addition, rate of
hospital acquired infections have been declining since recent past
according to statistics published by Office National Statistics, U.K.
Browse
Press Release Pipeline Analysis of Hospital Acquired Pneumonia
Drugs Market
http://www.transparencymarketresearch.com/pressrelease/hospital-acquired-pneumonia-drugs.htm
Key
companies in the market include Achaogen, Inc., Aridis
Pharmaceutical, AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bayer
Healthcare, Cubist Pharmaceutical, GlaxoSmithKline, Meiji Seika
Pharma Co., Ltd., Merck & Co., and Valneva SE.
Hospital
Acquired Pneumonia Drug Pipeline is as follows:
Global
Hospital Acquired Pneumonia Drug Pipeline, Late Stage Candidates
(Phase III)
- Tedizolid phosphate
- Ceftolozane/tazobactam
- Ceftazidime/avibactam
- Amikacin inhale
- Plazomicin
- Synflorix
Global
Hospital Acquired Pneumonia Drug Pipeline, Early Stage Candidates
(Phase II, Phase I and Preclinical Trials)
- AR-101 or KBPA101
- GSK 2189242A
- BAL30072
- MEDI4893
- AR 301 or KBSA301
- ME1100
- V114
- AR-104 or KBPA104
- AR-201 or KBRV201
- AR-401 or KBAB401
Browse
All Pharmaceutical Market Research Reports @
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About
Us
Transparency
Market Research (TMR) is a market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. TMR's
experienced team of Analysts, Researchers, and Consultants, use
proprietary data sources and various tools and techniques to gather
and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
Contact
Nachiket
90
State Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
No comments:
Post a Comment